Related Experiment Video

Updated: Aug 10, 2026

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings
14:40

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings

Published on: October 25, 2015

Perinatal corticosteroids: a review of the research. Part II: Postnatal administration

Isabel B Purdy1

  • 1University of California, Los Angeles, School of Nursing, 90095-6919, USA. ibpurdy@ucla.edu

Neonatal Network : NN
|June 9, 2004
PubMed

Insights

Dexamethasone may help premature infants with chronic lung disease (CLD), but clinicians must weigh its benefits against potential neurosensory risks. This review offers current evidence on dexamethasone use in neonatal intensive care units.

Area of Science:

  • Neonatal Medicine
  • Pediatric Pulmonology
  • Pharmacology

Background:

  • Postnatal corticosteroids, including dexamethasone, are used in neonatal intensive care units to prevent chronic lung disease (CLD) in preterm infants.
  • Guidelines issued in 2002 advised against routine systemic dexamethasone for CLD prevention in very low birth weight infants.

Purpose of the Study:

  • To review current evidence-based research and expert opinions on the use of dexamethasone in premature infants.
  • To inform neonatal clinicians about the benefits and potential adverse neurosensory risks associated with dexamethasone treatment.

Main Methods:

  • Systematic review of existing literature.
  • Synthesis of expert opinion on dexamethasone therapy.
  • Analysis of clinical trial data regarding efficacy and safety.

Main Results:

  • Dexamethasone demonstrates efficacy in reducing CLD severity and mortality in some preterm populations.
  • Potential adverse neurosensory outcomes, including developmental delays and cerebral palsy, are associated with dexamethasone exposure.
  • Risk-benefit analysis indicates a complex decision-making process for individual infants.

Conclusions:

  • The use of dexamethasone in premature infants requires careful consideration of individual patient factors and potential long-term neurodevelopmental effects.
  • Neonatal clinicians should stay informed about evolving research to optimize treatment strategies for CLD prevention and management.
  • Further research is needed to refine guidelines and minimize adverse outcomes associated with postnatal corticosteroid therapy.

More Related Videos

Intratracheal Instillation of Stem Cells in Term Neonatal Rats04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants06:39

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...